Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses
Eli Lilly And Co LLY faces renewed scrutiny as the FDA inspectors reveal additional manufacturing issues at its Branchburg, New Jersey plant. In a recent inspection conducted by the FDA in July, eight deficiencies were identified, ranging from problems in tracking the manufacturing process to…#elilillyand #lly #fda #branchburg #newjersey #elilillys #trulicity #erbitux #cyramza #elililly (Source: Reuters: Health)
Source: Reuters: Health - January 19, 2024 Category: Consumer Health News Source Type: news

Could Cetuximab Maintenance Play a Role in RAS Wild-Type Metastatic CRC?
(MedPage Today) -- Maintenance therapy with cetuximab (Erbitux) after FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus cetuximab induction therapy led to better outcomes for patients with RAS wild-type metastatic colorectal cancer (CRC... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 18, 2023 Category: Gastroenterology Source Type: news

What Are Treatments for Recurrent Respiratory Papillomatosis?
Discussion Human papilloma virus (HPV) is a member of the Papillomaviridae virus family with over a 150 different subtypes. HPV can cause cervical, genital and respiratory tract papillomas. HPV is often benign but can cause anogenital, cervical and head and neck cancers. Recurrent respiratory papillomatosis (RRP) is uncommon but can cause significant morbidity while awaiting the body’s immune system to respond. There is a juvenile and adult form, and the incidence varies between 2-4/100,000 in the pediatric population. The juvenile form frequently occurs between 3.6-6 years of age and in general the younger the patie...
Source: PediatricEducation.org - July 31, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Lupin Partners Enzene to roll out biosimilar Cetuximab here
In July 2009, the US Food and Drug Administration (USFDA) approved Eli Lilly and Merck's cetuximab (Erbitux) for treatment of metastatic colorectal cancer and head and neck cancer. Head and neck cancer presents a significant public health challenge in India, with a staggering annual incidence of over 100,000 new cases. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 30, 2023 Category: Pharmaceuticals Source Type: news

Lupin launches biosimilar cetuximab in pact with Enzene
Cetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer (Source: The Economic Times)
Source: The Economic Times - May 30, 2023 Category: Consumer Health News Source Type: news

Roche presents positive phase Ib data at AACR 2023, reinforcing the potential of its KRAS G12C inhibitor divarasib in advanced solid tumours
In the phaseIb GO42144 study,divarasib in combination withcetuximab, an anti-EGFR therapy, led to a confirmed overall response in 62% of people with advanced colorectal cancerThe treatment combination demonstrated a manageable safety profileThe data presented at AACR 2023further support Roche ' s programme to developdivarasib as single-agent or in combination for treating solid tumoursBasel, 18 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from the phase Ib GO42144 study, which show that treatment with the KRAS G12C inhibitor, divarasib (GDC-6036), in combination with anti-EGFR therapy, ...
Source: Roche Investor Update - April 18, 2023 Category: Pharmaceuticals Source Type: news

Mirati Drug Combination Shrinks Tumors in 39% of Patients in Colon Cancer Study Mirati Drug Combination Shrinks Tumors in 39% of Patients in Colon Cancer Study
A combination of adagrasib and older cancer drug Erbitux shrank tumors in 39% of patients with advanced colorectal cancer treated in a small trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 21, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Novel BRAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors Novel BRAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors
First-in-human study shows a novel, topically applied cream appears to ameliorate the acneiform rash seen with EGFR inhibitors such as cetuximab and panitumumab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA approves new dosing regimen for cetuximab
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Encorafenib + cetuximab ± binimetinib in BRAF V600E-mutated metastatic colorectal cancer: benefits at high cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

< i > Oncotarget < /i > : Combination of copanlisib with cetuximab improves tumor response
(Impact Journals LLC) " These data support further investigation of PI3K inhibition in HNSCC and suggests gene expression patterns associated with PI3K signaling " (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 10, 2021 Category: Biology Source Type: news

Triple Treatment Combo Beneficial in BRAF - Mutant CRC
Irinotecan, cetuximab, and vemurafenib improve progression - free survival in BRAFV600E - mutated colorectal cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 28, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Triple Treatment Combo Beneficial in BRAF-Mutant CRC
MONDAY, Dec. 28, 2020 -- Irinotecan and cetuximab combined with vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer (CRC), according to a study published online Dec. 23 in the Journal of Clinical Oncology. Scott... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2020 Category: Pharmaceuticals Source Type: news

Triple chemotherapy combination improves metastatic colorectal cancer outcomes
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination -- of irinotecan, cetuximab, and vemurafenib -- is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2020 Category: Cancer & Oncology Source Type: news

Erbitux (cetuximab)
Title: Erbitux (cetuximab)Category: MedicationsCreated: 12/4/2020 12:00:00 AMLast Editorial Review: 12/4/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 4, 2020 Category: Cancer & Oncology Source Type: news